Permeating the blood brain barrier and Abrogating the inflammation in stroke

Implications for stroke therapy

Cesar V. Borlongan, Loren E. Glover, P. R. Sanberg, David C Hess

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.

Original languageEnglish (US)
Pages (from-to)3670-3676
Number of pages7
JournalCurrent Pharmaceutical Design
Volume18
Issue number25
DOIs
StatePublished - Oct 22 2012

Fingerprint

Blood-Brain Barrier
Stroke
Inflammation
Cell- and Tissue-Based Therapy
NF-kappa B
Brain
Mannitol
Stem Cells
Therapeutics
Therapeutic Uses
Nervous System Diseases
Fetal Blood

Keywords

  • Blood brain barrier
  • Cerebral palsy
  • Mannitol
  • Neurotrophic factor
  • NF-kB
  • Stem cells
  • Transplantation

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Permeating the blood brain barrier and Abrogating the inflammation in stroke : Implications for stroke therapy. / Borlongan, Cesar V.; Glover, Loren E.; Sanberg, P. R.; Hess, David C.

In: Current Pharmaceutical Design, Vol. 18, No. 25, 22.10.2012, p. 3670-3676.

Research output: Contribution to journalReview article

Borlongan, Cesar V. ; Glover, Loren E. ; Sanberg, P. R. ; Hess, David C. / Permeating the blood brain barrier and Abrogating the inflammation in stroke : Implications for stroke therapy. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 25. pp. 3670-3676.
@article{55764960c86d42f493da4dec1b5ad9a7,
title = "Permeating the blood brain barrier and Abrogating the inflammation in stroke: Implications for stroke therapy",
abstract = "Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.",
keywords = "Blood brain barrier, Cerebral palsy, Mannitol, Neurotrophic factor, NF-kB, Stem cells, Transplantation",
author = "Borlongan, {Cesar V.} and Glover, {Loren E.} and Sanberg, {P. R.} and Hess, {David C}",
year = "2012",
month = "10",
day = "22",
doi = "10.2174/138161212802002841",
language = "English (US)",
volume = "18",
pages = "3670--3676",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "25",

}

TY - JOUR

T1 - Permeating the blood brain barrier and Abrogating the inflammation in stroke

T2 - Implications for stroke therapy

AU - Borlongan, Cesar V.

AU - Glover, Loren E.

AU - Sanberg, P. R.

AU - Hess, David C

PY - 2012/10/22

Y1 - 2012/10/22

N2 - Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.

AB - Cell therapy has been shown as a potential treatment for stroke and other neurological disorders. Human umbilical cord blood (HUCB) may be a promising source of stem cells for cell therapy. The most desired outcomes occur when stem cells cross the blood brain barrier (BBB) and eventually reach the injured brain site. We propose, from our previous studies, that mannitol is capable of disrupting the BBB, allowing the transplanted cells to enter the brain from the periphery. However, when the BBB is compromised, the inflammatory response from circulation may also be able to penetrate the brain and thus may actually exacerbate the stroke rather than afford therapeutic effects. We discuss how an NF-kB decoy can inhibit the inflammatory responses in the stroke brain thereby reducing the negative effects associated with BBB disruption. In this review, we propose the combination of mannitol-induced BBB permeation and NF-kB decoy for enhancing the therapeutic benefits of cell therapy in stroke.

KW - Blood brain barrier

KW - Cerebral palsy

KW - Mannitol

KW - Neurotrophic factor

KW - NF-kB

KW - Stem cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84867535127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867535127&partnerID=8YFLogxK

U2 - 10.2174/138161212802002841

DO - 10.2174/138161212802002841

M3 - Review article

VL - 18

SP - 3670

EP - 3676

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 25

ER -